Lv4
531 积分 2021-01-18 加入
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
3个月前
已完结
The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
3个月前
已完结
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
3个月前
已完结
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
4个月前
已完结
Unexpectedly High Incidence of Immune-Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab-Including Chemotherapy
4个月前
已关闭
Abstract 3228: Characterization of multi-organ system involvement of immune-related adverse events after anti-PD-(L)1 monotherapies: A pooled analysis of clinical trial data submitted to FDA
4个月前
已完结
A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience
5个月前
已完结
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
5个月前
已完结
皖公网安备34019202002308
